Tenon Medical, Inc. (TNON): M&A transaction — Tenon Medical acquires SiVantage and SIMPL Medical assets, hires former SiVantage founders as executives

Tenon Medical, Inc.

Acquired substantially all assets of SiVantage (SImmetry) and SIMPL Medical on Aug 1, 2025, for cash, stock, and royalties.
SImmetry consideration includes $750K cash, 710,300 shares (473,533 pledged for 1 year), royalty 15%/10% over 5 years (cap $5M), up to $1.3M deferred cash, and earnout shares.
SIMPL consideration: 30% royalty on net revenue for 5 years (20% after aggregate exceeds $20M); optional stock payment up to 33.3% of quarterly royalty.
Wyatt Geist named Chief Innovation Officer, Nate Grawey named Chief Commercial Officer; each gets $290K base salary and 138,114 restricted shares.
Portfolio now includes SImmetry, SImmetry+, and SIMPL products, making Tenon a multi-approach sacro-pelvic fusion company.

item 1.01 item 2.01 item 3.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Tenon Medical, Inc. completed an acquisition involving SiVantage, Inc. (closed 2025-08-01).

Action: acquisition
Counterparty: SiVantage, Inc.
Closing: 2025-08-01

Exact text from the filing

On August 1, 2025 (the “SI Closing Date”), Tenon Medical, Inc. (the “Company”), entered into an asset purchase agreement (the “SI APA”) by and between the Company and SiVantage, Inc., a Delaware corporation (“SI”), pursuant to which the Company acquired substantially all of the assets of SI (the “SImmetry Business”)

View on SEC.gov

5 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Tenon Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-072781

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.